Ningbo Junan Pharmaceutical Technology

Ningbo Junan Pharmaceutical Technology is a high-tech biopharmaceutical company based in Ningbo, China, specializing in the development, manufacture, and sale of radiopharmaceuticals and specialized medical devices for cancer treatment. As a subsidiary of China Isotope & Radiation Corporation (CIRC), the company is a leading provider of Iodine-125 (125I) radioactive seeds, which are widely used in brachytherapy for various solid tumors, including prostate, lung, and pancreatic cancers. Its product portfolio also includes Strontium-89 chloride injections for the treatment of bone pain associated with metastatic cancer, as well as specialized implantation equipment such as protection guns and cabins. The company operates under strict GMP standards and has been recognized as a national high-tech enterprise with numerous patents in the field of nuclear medicine. Following its acquisition by CIRC in 2019, the company has continued to expand its market presence and technological capabilities in the radiopharmaceutical sector.